Scientific Advisory Board
ERX Pharmaceuticals’ scientific advisory board is comprised of an internationally-renowned group of advisors who are experts in the fields of obesity-related, and specifically leptin-related biology, pharmaceutical chemistry, and drug development strategy and execution.
John Amatruda, M.D.
Former SVP and Franchise Head for Diabetes and Obesity, Merck
Louis Aronne, M.D.
Professor of Metabolic Research, Weill-Cornell Medical College, Vice-Chairman of the Board of the American Board of Obesity Medicine
Andy Bodnar, M.D., J.D.
Former SVP, Strategy & Medical & External Affairs, Bristol-Myers Squibb
Jeffrey M. Friedman, M.D., Ph.D.
Professor, Rockefeller University, Howard Hughes Medical Institute
Tamas Horvath, M.D., Ph.D.
Professor, Chair of Comparative Medicine, Professor of Neurobiology, Yale School of Medicine
Takashi Kadowaki, M.D., Ph.D.
Professor, Chairman of Japanese Diabetes Society, University of Tokyo, Japan
C. Ronald Kahn, M.D.
Chief Academic Officer and Senior Investigator, Joslin Diabetes Center, Professor of Medicine, Harvard Medical School
Ralph Mazitschek, Ph.D.
Assistant Professor, Harvard Medical School, Massachusetts General Hospital, Member of Broad Institute/MIT
Sir Stephen O’Rahilly, M.D.
Professor of Clinical Biochemistry & Medicine, University of Cambridge, U.K.
Nancy Thornberry, Ph.D.
Former SVP and Franchise Head for Diabetes and Obesity, Merck
Matthias H. Tschöp, M.D.
Professor, Chair of Division of Metabolic Diseases, Technische Universität München, Germany
Kohjiro Ueki, M.D., Ph.D.
Director of Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan